Tag: Coronavirus

1. Hospital readmission and all-cause mortality rates are 3.5 and 7.7 times higher in COVID-19 patients after discharge, than the general population. 2. In addition to respiratory illness, COVID-19 patients experienced higher rates of diagnosis of a major adverse cardiovascular event, diabetes, chronic kidney disease, and chronic liver disease. Evidence Rating...
1. Tislelizumab, a monoclonal antibody and PD1/L1 inhibitor, when combined with chemotherapy, showed significantly prolonged progression free survival and higher objective response rate, compared with chemotherapy alone. Evidence Rating Level: 1 (Excellent) Squamous non-small-cell lung cancers (sq-NSCLCs) are often diagnosed at a later stage, leading to poor prognosis and difficult disease management....
1. 80% of patients in the azithromycin plus usual care group reported feeling recovered within 28 days, compared to 77% in the usual care group. 2. Safety outcomes were similar in both groups with 1% of patients reporting hospital admission and no deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Treatments that...
1. Among a large U.S. cohort, previous infection with SARS-CoV-2 appears to confer high levels of immunity against reinfection for at least 8 months. Evidence Level Rating: 2 (Good) As of early March 2021, SARS-CoV-2 has infected nearly 120 million individuals worldwide. The subsequent duration of immunity to reinfection is unknown; infection...
1. 80% of patients in the azithromycin plus usual care group reported feeling recovered within 28 days, compared to 77% in the usual care group. 2. Safety outcomes were similar in both groups with 1% of patients reporting hospital admission and no deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Treatments that...
1. A cross-sectional sample of residents from Wuhan, China showed low overall seroprevalence (6.92%) of anti-SARS-CoV-2 antibodies in April 2020. 2. Adjusted seroprevalence was lower amongst self-reported asymptomatic individuals than those with symptoms. Evidence Rating Level: 2 (Good) Study Rundown: Over a year after the novel coronavirus SARS-CoV-2 (COVID-19) was characterized as...
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there were no hospital admissions for COVID-19 in the ChAdOx1-nCoV-19 group.  Evidence Rating Level: 1 (Excellent) Study Rundown: At the time of this publication, the COVID-19 pandemic continues to burden healthcare systems...
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2. Treatment with tocilizumab did not improve survival among patients. Evidence Rating Level: 1 (Excellent) Study Rundown: Cases pertaining to the coronavirus disease 2019 (Covid-19) have led to severe clinical manifestations...
1. Patients hospitalized with COVID-19 and treated with dexamethasone showed an overall decrease in 28-day mortality compared to those treated with usual care. 2. Dexamethasone treatment had a shorter duration in hospital stay compared to the usual care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Although the majority of coronavirus disease 2019 (COVID-19)...
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2. Treatment with tocilizumab did not improve survival among patients. Evidence Rating Level: 1 (Excellent) Study Rundown: Cases pertaining to the coronavirus disease 2019 (Covid-19) have led to severe...